To our knowledge, this is the first aggregate meta‐analysis to attempt to evaluate whether the combination of SGLT2 and RAAS inhibitors provides better cardio‐renal clinical outcomes in patients with type 2 diabetes compared with SGLT2‐Is alone. Here, SLC5A2 is linked to type 2 diabetes mellitus.